Post-Market watch: tracking a leukemia Drug's Real-World safety
NCT ID NCT05923112
Summary
This study monitored the safety and effectiveness of the approved drug BESPONSA in real-world patients in Japan. It included 421 adults and children with a specific type of acute lymphocytic leukemia that had returned or was not responding to other treatments. The main goal was to track side effects and patient outcomes for up to a year after starting treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.